

Photocure
Profit & Loss

(all amounts in NOK 1,000 except per share data)

Q4 2008	Q4 2007		2008 1.1-31.12	2007 1.1-31.12
33 190	23 587	Sales revenues	100 917	75 252
0	3 908	Signing fee and milestone revenues	1 303	23 754
33 190	27 495	Total revenues	102 220	99 006
-5 914	-2 967	Cost of products sold	-19 074	-17 326
27 277	24 528	Gross profit	83 147	81 679
1 223	3 187	Other income	6 257	7 625
-1 787	-1 598	Indirect manufacturing expenses	-8 607	-8 512
-25 508	-28 873	Research and development expenses	-84 303	-112 098
-12 559	-11 429	Marketing and sales expenses	-45 916	-39 766
-3 113	-6 114	General and administrative expenses	-17 951	-16 378
-14 469	-20 300	Operating profit/loss(-)	-67 374	-87 450
7 649	4 652	Financial income	16 103	14 224
-2 427	-661	Financial expenses	-13 111	-1 744
5 222	3 991	Net financial profit/loss(-)	2 991	12 480
-9 246	-16 308	Profit/loss(-) before tax	-64 382	-74 970
0	0	Tax expenses	0	0
-9 246	-16 308	Net profit/loss(-)	-64 382	-74 970
-	-45	Incl. minority interests in the amount of	-	-773
-0.42	-0.74	Net income/loss(-) per share, undiluted (1)	-2.91	-3.40
-0.42	-0.74	Net income/loss(-) per share, diluted (2)	-2.91	-3.39

(1) Undiluted income/loss per share is calculation based on average weighted number of shares outstanding.

(2) Diluted income per share is calculated adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

Income statement 4th quarter 2008 - own sales/partner sales

	4Q 2008			% vs. PY	4Q 2007				
	Own	Partner	R&D*		Total	Own	Partner	R&D*	Total
Sales revenue	10 789	22 401	0	33 190	41 %	9 630	13 956	0	23 587
Milestone revenue	0	0	0	0		0	3 908	0	3 908
Total revenues	10 789	22 401	0	33 190	21 %	9 630	17 865	0	27 495
Cost of goods sold	810	5 104	0	5 914	99 %	589	2 378	0	2 967
Gross profit	9 980	17 297	0	27 277	11 %	9 041	15 487	0	24 528
Gross profit (ex milestones)	92 %	77 %		82 %		94 %	83 %		87 %
Operating expenses	10 729	3 236	27 780	41 745	-7 %	11 101	3 892	29 833	44 827
Operating profit	-749	14 061	-27 780	-14 469	-29 %	-2 060	11 595	-29 833	-20 299
Net finance	0	0	0	5 222	31 %	0	0	0	3 991
Profit before tax	-749	14 061	-27 780	-9 246	-43 %	-2 060	11 595	-29 833	-16 308

* Including share of general and administrative expenses

Sales revenues - product split

	4Q 2008			% vs. PY	4Q 2007		
	Own	Partner	Total		Own	Partner	Total
Metvix/Aktlite	7 421	12 223	19 644	33 %	7 642	7 149	14 791
Hexvix	3 368	10 178	13 546	54 %	1 988	6 807	8 795
Total	10 789	22 401	33 190	41 %	9 630	13 956	23 587

Income statement per segment 2008

	2008			% vs. PY	2007				
	Own	Partner	R&D*		Total	Own	Partner	R&D*	Total
Sales revenue	35 085	65 832	0	100 917	34 %	29 069	46 183	0	75 252
Milestone revenue	0	1 303	0	1 303		0	23 754	0	23 754
Total revenues	35 085	67 135	0	102 220	3 %	29 069	69 937	0	99 006
Cost of goods sold	2 431	16 643	0	19 074	10 %	2 514	14 812	0	17 326
Gross profit	32 654	50 492	0	83 146	2 %	26 555	55 125	0	81 680
Gross profit (ex milestones)	93 %	75 %		81 %		91 %	68 %		77 %
Operating expenses	39 110	17 414	93 997	150 521	-11 %	35 863	14 605	118 661	169 129
Operating profit	-6 456	33 078	-93 997	-67 374	-23 %	-9 308	40 519	-118 661	-87 449
Net finance	0	0	0	2 991		0	0	0	12 479
Profit before tax	-6 456	33 078	-93 997	-64 382	-14 %	-9 308	40 519	-118 661	-74 970

* Including share of general and administrative expenses

Sales revenue - product split

	2008			% vs. PY	2007		
	Own	Partner	Total		Own	Partner	Total
Metvix/Aktlite	24 895	39 168	64 063	18 %	23 053	31 168	54 221
Hexvix	10 190	26 664	36 855	75 %	6 016	15 016	21 031
Total	35 085	65 832	100 917	34 %	29 069	46 183	75 252

Balance Sheet (all amounts in NOK 1,000)

	31.12.2008	31.12.2007
Intangible assets, software	534	779
Machinery & equipment	3 939	3 436
Other investments	11 528	0
Total non-current assets	16 001	4 215
Inventory	12 792	12 504
Receivables	29 158	32 222
Cash & cash equivalents	179 897	252 452
Total current assets	221 846	297 179
Total assets	237 847	301 394
Paid-in capital	11 047	11 047
Other paid-in capital	15 467	10 984
Retained earnings	173 181	237 472
Shareholders' equity	199 694	259 503
Minority interest		491
Total equity	199 694	259 994
Current liabilities	38 153	41 400
Total liabilities	38 153	41 400
Total equity and liabilities	237 847	301 394

Changes in equity (all amounts in NOK 1,000)

Q4 2008	Q4 2007		2008 1.1-31.12	2007 1.1-31.12
208 560	274 790	Equity at beginning of period	259 994	326 935
0	0	Share issue, employees	0	2 165
0	0	Share issue	0	1 720
380	1 532	Share-based compensation	4 483	4 163
0	-20	De-merger of PCI Biotech/ Investment	-45 715	-20
0	0	Net gain de-consolidation PCI Biotech	45 315	0
-9 246	-16 308	Net income/loss(-) for the period	-64 382	-74 970
199 694	259 994	Equity at end of period	199 694	259 994

Cash Flow Statement (all amounts in NOK 1,000)

Q4 2008	Q4 2007		2008 1.1-31.12	2007 1.1-31.12
-9 246	-16 308	Income/loss(-) before tax	-64 382	-74 970
16 805	-7 332	Other operational items	4 704	-20 685
7 559	-23 640	Net cash flow from operations	-59 679	-95 655
-6 138	4 415	Cash flow from investments	-12 864	9 450
-3 101	-3	Cash flow from capital transactions	-13	3 572
-1 680	-19 229	Net change in cash during the period	-72 555	-82 633
181 578	271 682	Cash & cash equivalents at beginning of period	252 452	335 085
179 897	252 453	Cash & cash equivalents at end of period	179 897	252 452